Locations:
Search IconSearch
September 17, 2021/Cancer

Techniques and Lessons Learned: What to Know About Single-Port Extraperitoneal Radical Prostatectomy

Early experiences and outcomes on the brink of 200 cases

Single-port robot

Cleveland Clinic was the first U.S. medical center to begin using the single-port (SP) robot for urologic procedures in late 2018. Since then, experts at Glickman Urological & Kidney Institute continue to fine-tune their surgical technique.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Jihad Kaouk, MD, Director of the Center for Robotic and Image-Guided Surgery and the Zegarac-Pollock Endowed Chair in Laparoscopic and Robotic Surgery, elaborates on the benefits of performing the prostate cancer surgery extraperitoneally, noting, “By avoiding the sac in which the bowel is contained, the surgery is compartmentalized, limited to the area just around the prostate. The gas bubble in which the robotic arms work expands the peritoneum, pushing the bowel out of the way, allowing better visibility.”

In addition, the SP robotic technique avoids the steep Trendelenburg positioning, which improves recovery time and mitigates potential risks associated with such positioning, including optical nerve edema, congestion and respiratory problems during surgery. Patients undergoing the procedure with SP robotic prostatectomy lie flat. They experience a single incision, versus the five incisions required in a patient’s abdomen in previous robotic radical prostatectomy procedures.

These key differences in the SP robotic technique allow for easier extraperitoneal access, which helps avoid intra-abdominal adhesions. The technique also avoids assistant ports. Improved recovery aspects of the SP robotic procedure include decreased opioid use (70 percent of patients do not use opioids), an increase in same-day discharges with a median hospital stay of 4.8 hours, no drains and no reported ileus, with good functional and oncologic outcomes. Nearly 90 percent of patients were continent at six months.

Advertisement

The team shared their experience using the SP robot to perform extraperitoneal radical prostatectomy in 185 cases at the American Urological Association 2021 Annual Meeting.

Learn more in their virtual presentation:

SP Extraperitoneal Radical Prostatectomy: Technique and Lessons on the Brink of 200 Cases (Graphic)

Advertisement

Related Articles

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

Ad